Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › DMARDs

DMARDs

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of DMARDs

6 trials tracked of DMARDs: 6 in phase 3 or 4 and 3 with published results. The most-cited published study has 53 citations.

6Trials tracked
6Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 4 3 Phase 3 3
  1. Phase 4 RHYTHM (Formerly Escape II Myocardium) Completed · 53 cited
  2. Phase 3 A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent Completed · 37 cited
  3. Phase 3 A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants Completed · 37 cited
  4. Phase 4 A Long-term Safety Extension Study of Tocilizumab in Brazilian Participants With Rheumatoid Arthritis (RA) Who Completed the Studies ML21530 and MA21488 Completed
  5. Phase 4 Rheumatoid Arthritis Memory B Cells and Abatacept Completed
  6. Phase 3 A Study of Tocilizumab in Combination With Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Moderate to Severe Active Rheumatoid Arthritis With an Inadequate Response to DMARDs Completed

Showing the 6 most-cited and recently-updated of 6 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Late-onset rheumatoid arthritis shows higher DAS28 scores and lower remission rates compared to young-onset disease in a meta-analysis
Rheumatology Meta-analysis
Late-onset rheumatoid arthritis shows higher DAS28 scores and lower remission rates compared to young-onset disease in a meta-analysis Meta-analysis compares treatment outcomes in older versus younger rheumatoid arthritis patients
This meta-analysis reviewed data from over 5000 patients with late-onset rheumatoid arthritis (LORA) and young-onset rheumatoid arthritis (Y…
A large review found older patients with rheumatoid arthritis had higher disease activity and lower remission rates on biologics compared to…
May 1, 2026